| Literature DB >> 34349826 |
De-Hui Li1, Yi-Fan Su1,2, Huan-Fang Fan1, Na Guo1, Chun-Xia Sun1.
Abstract
OBJECTIVE: The purpose of this study was to systematically evaluate the efficacy and safety of acupuncture combined with the WHO three-step analgesic drug ladder for cancer pain.Entities:
Year: 2021 PMID: 34349826 PMCID: PMC8328698 DOI: 10.1155/2021/5558590
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flowchart of the literature review and selection process.
Summary of randomised clinical studies of acupuncture combined with three-step analgesic drug therapy for the treatment of cancer pain.
| Study (year) | Type of cancer | Sample sizes | Interventions | Acupuncture point selection | Session frequency and duration | Main outcomes and assessment of pain | ||
|---|---|---|---|---|---|---|---|---|
| T | C | T | C | |||||
| Wang (2018) [ | Various | 35 | 35 | AT + C | Drug (three-step analgesic ladder) | LI4, LR3, and Ashi point | 30 min qd 6 weeks | Response rate, NRS, and side effect rate |
|
| ||||||||
| Wang (2016) [ | Lung cancer | 30 | 30 | EA + C | Oxycodone sustained-release tablets | LI4, PC6, ST36, and SP6 | 30 min qd 14 days | Response rate, NRS, side effect rate, burst pain, onset time, and DOR |
|
| ||||||||
| Zhong (2016) [ | Various | 30 | 30 | FA + C | Morphine sulfate sustained-release tablets | Ashi point | Once a day 14 days | Response rate, QOL, and burst pain |
|
| ||||||||
| Mi (2010) [ | Gastric cancer | 32 | 30 | FN + AT + C | Drug (three-step analgesic ladder) | FN: BL21, BL18, and BL17. AT: CV12, ST25, and St36 | 30 min qod 4 weeks | Response rate and side effect rate |
|
| ||||||||
| Bai (2019) [ | Various | 50 | 50 | FN + C | Drug (three-step analgesic ladder) | Ashi point, ST36, and SP6 | qod 14 days | Response rate, NRS, and side effect rate |
|
| ||||||||
| Liu (2018) [ | Various | 72 | 75 | TEAS + C | Drug (three-step analgesic ladder) | LI4, PC6, ST36, and SP6 | 30 min bid 3 weeks | Response rate, BPI-S, KPS, and side effect rate |
|
| ||||||||
| Liu (2011) [ | Liver cancer | 30 | 30 | AT + C | Tramadol hydrochloride sustained-release tablets | SP4, PC6, GB41, TE5, SI3, BL62, LU7, KI6, LR3, and LR14 | qd 14 days | Response rate, NRS, QOL, side effect rate, onset time, and DOR |
|
| ||||||||
| Fu (2019) [ | Various | 16/16 | 16 | AT + C | Morphine hydrochloride sustained-release tablets | PC6 and SP6 | 1 h qd | Response rate, NRS, KPS, side effect rate, burst pain, onset time, and DOR |
| WA + C | ||||||||
|
| ||||||||
| Wu (2019) [ | Various | 30 | 30 | WA + C | Drug (three-step analgesic ladder) | Based on syndrome differentiation and disease differentiation | 12 h qd 10 days | Response rate, VAS, burst pain, and side effect rate |
|
| ||||||||
| Dong (2018) [ | Various | 60 | 60 | WA + C | Drug (three-step analgesic ladder) | Based on syndrome differentiation and disease differentiation | 10–12 h qd 7 days | Response rate, NRS, QLQ-C30, and side effect rate |
|
| ||||||||
| Sun (2016) [ | Various | 30 | 30 | AT + C | Oxycodone | LI4, PC6, ST36, SP6, Ashi point, and others | 30 min qd 14 days | Response rate, NRS, KPS, QOL, and side effect rate |
|
| ||||||||
| Zhang (2014) [ | Various | 30 | 30 | AT + C | Drug (three-step analgesic ladder) | LI4 and ST36. Lung cancer: PC6 and LU6. Liver cancer: GB34, LR6, and LR3. Colorectal cancer: PC6, CV12, and TE6 | 30 min qd 7 days | Response rate, QOL, side effect rate, onset time, and DOR |
|
| ||||||||
| Hui (2019) [ | Various | 40 | 40 | AT + C | Drug (three-step analgesic ladder) | Ashi point, LI4, GV14, BL11, GB34, and LR3 | 30 min qd 14 days | Response rate, side effect rate, onset time, and DOR |
|
| ||||||||
| Tan (2012) [ | Various | 106 | 101 | AT + C | Drug (three-step analgesic ladder) | LI4 and PC6. Lung cancer: LU6. Liver cancer: GB34 and LR6. Colorectal cancer: CV12, ST36, and TE6 | 0.5–1 h qd 3 weeks | Response rate and side effect rate |
|
| ||||||||
| Fan (2017) [ | Lung cancer | 35 | 34 | AT + C | Drug (three-step analgesic ladder) | PC6, LI4, ST36, GB34, and SP6 | 20 min qd 20 days | Response rate, NRS, onset time, and DOR |
|
| ||||||||
| Jiang (2016) [ | Various | 25 | 25 | AT + C | Drug (three-step analgesic ladder) | Ashi point, LR3, and LI4 | 30 min qd 7 days | Response rate and NRS |
|
| ||||||||
| Li (2017) [ | Gastric cancer | 30 | 30 | AT + C | Drug (three-step analgesic ladder) | ST36, LR3, and LI4 | 30 min qd 7 days | Response rate, NRS, QOL, and side effect rate |
|
| ||||||||
| Huang (2018) [ | Various | 31 | 31 | AT + C | Drug (three-step analgesic ladder) | PC6. Lung cancer: LI4, LU4, LU6, and ST36. Liver cancer: GB34 and LR3. Breast cancer: LI4, STI8, and CV9. Gastric cancer: CV12, ST36, and TE6 | 30 min qd 7 days | Response rate |
|
| ||||||||
| Peng (2012) [ | Various | 23 | 24 | EA + C | Drug (three-step analgesic ladder) | LI4, PC6, ST36, and SP6 | 30 min qd 7 days | Response rate, onset time, and DOR |
T: treatment group, C: control group, AT: acupuncture, EA: electroacupuncture, FA: floating acupuncture, FN: fire needle, WA: wrist-ankle acupuncture, DOR: duration of response, NRS: numerical rating scale, BPI-S: brief pain inventory-severity, QOL: quality of life, and KPS: Karnofsky performance status.
Risk of bias for the 19 included studies using a modified approach to the Cochrane risk of bias tool.
| Risk of bias | Trial characteristics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Source | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessors | Infrequent loss to follow-up | Free of selective outcome reporting | Free of other types of bias | Statistical analysis (per protocol, intention to treat, etc.) | How is loss to follow-up handled? | Adverse event |
| Wang (2018) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely no | Definitely no | Definitely no | Not mentioned | Ignored | Yes |
|
| ||||||||||
| Wang (2016) [ | Probably yes | Probably yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Zhong (2016) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely yes | Definitely no | Probably yes | Per protocol | Not mentioned | No |
|
| ||||||||||
| Mi (2010) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Bai (2019) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Liu (2018) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely no | Definitely yes | Probably yes | Not mentioned | Ignored | Yes |
|
| ||||||||||
| Liu (2011) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Fu (2019) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely no | Definitely no | Definitely no | Per protocol | Ignored | Yes |
|
| ||||||||||
| Wu (2019) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely yes | Definitely no | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Dong (2018) [ | Probably yes | Probably yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Sun (2016) [ | Probably yes | Probably yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Zhang (2014) [ | Probably yes | Probably yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Per protocol | Not mentioned | Yes |
|
| ||||||||||
| Hui (2019) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Tan (2012) [ | Probably yes | Probably yes | Probably no | Probably no | Definitely yes | Definitely no | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Fan (2017) [ | Definitely yes | Definitely yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Per protocol | Not mentioned | No |
|
| ||||||||||
| Jiang (2016) [ | Probably yes | Probably yes | Probably no | Probably no | Definitely yes | Definitely no | Probably yes | Per protocol | Not mentioned | No |
|
| ||||||||||
| Li (2017) [ | Probably yes | Probably yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Not mentioned | Not mentioned | Yes |
|
| ||||||||||
| Huang (2018) [ | Probably yes | Probably yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Not mentioned | Not mentioned | No |
|
| ||||||||||
| Peng (2012) [ | Probably yes | Probably yes | Probably no | Probably no | Definitely yes | Definitely yes | Probably yes | Per protocol | Not mentioned | No |
Figure 2Cochrane risk of bias by trial.
Figure 3Forest plot of the total response rates of acupuncture combined with three-step analgesic drugs versus three-step analgesic drugs alone for cancer pain.
Figure 4Forest plot of NRS score of acupuncture combined with three-step analgesic drugs versus three-step analgesic drugs alone for cancer pain.
Figure 5Forest plot of side effect rates of acupuncture combined with three-step analgesic drugs versus three-step analgesic drugs alone for cancer pain.
Figure 6Forest plot of times of burst pain of acupuncture combined with three-step analgesic drugs versus three-step analgesic drugs alone for cancer pain.
Figure 7Forest plot of the onset time of acupuncture combined with three-step analgesic drugs versus three-step analgesic drugs alone for cancer pain.
Figure 8Forest plot of the duration of response of acupuncture combined with three-step analgesic drugs versus three-step analgesic drugs alone for cancer pain.
Figure 9Total efficiency funnel.